中医临床研究
中醫臨床研究
중의림상연구
CLINICAL JOURNAL OF CHINESE MEDICINE
2015年
3期
62-65
,共4页
尼妥珠单抗%药疹%梅花针%活血解毒法
尼妥珠單抗%藥疹%梅花針%活血解毒法
니타주단항%약진%매화침%활혈해독법
Nimotuzumab%Epispasis%Percussopunctator%Promoting blood circulation and detoxication
目的：观察梅花针叩刺联合活血解毒中药用于治疗尼妥珠单抗联合化疗过程中反应性药疹，以期为更好的提高晚期肿瘤患者药物依从性及生活质量提供论据支持。方法：90例晚期肿瘤患者均接受尼妥珠单抗联合其他化疗药的治疗，2周后评价按RECIST标准实体瘤情况，并根据是否产生药疹将其随机分为实验组及对照组。实验组行梅花针局部叩刺联合白花蛇舌草、苦参等活血解毒药物进行干预，对照组行生理盐水干预。经过2周与6周的综合治疗再次评估药疹变化情况；药疹标准参考加拿大国立癌症研究所扩大通用性标准（NCIC GTG分级）。结果：56例有药疹发生，且其实体瘤评估控制率与有效率与无药疹发生病例无明显差别；进一步评估56例入组药疹患者不同处理后药疹的变化情况，随机分成2组每组各28人，分中医外治干预组及空白对照组。治疗2周：出疹的患者实验组1级药疹率50%，2级39.3%，3级10.7%，实验组药疹情况控制于1级（P＜0.05），实验组2级、3级药疹的发病率显著低于对照组（P＜0.05）。治疗6周：实验组出现1级药疹35.7%，2级50%，3级14.3%；对照组3级42.9%，4级14.3%，实验组药疹控制在1级与2级（P＜0.05），3级药疹的发病率显著低于对照组（P＜0.05）。结论：本研究表明，药疹与尼妥珠单抗药效无明显对应关系，同时活针药结合法可显著改善由于尼妥珠单抗联合化疗产生的药疹。
目的：觀察梅花針叩刺聯閤活血解毒中藥用于治療尼妥珠單抗聯閤化療過程中反應性藥疹，以期為更好的提高晚期腫瘤患者藥物依從性及生活質量提供論據支持。方法：90例晚期腫瘤患者均接受尼妥珠單抗聯閤其他化療藥的治療，2週後評價按RECIST標準實體瘤情況，併根據是否產生藥疹將其隨機分為實驗組及對照組。實驗組行梅花針跼部叩刺聯閤白花蛇舌草、苦參等活血解毒藥物進行榦預，對照組行生理鹽水榦預。經過2週與6週的綜閤治療再次評估藥疹變化情況；藥疹標準參攷加拿大國立癌癥研究所擴大通用性標準（NCIC GTG分級）。結果：56例有藥疹髮生，且其實體瘤評估控製率與有效率與無藥疹髮生病例無明顯差彆；進一步評估56例入組藥疹患者不同處理後藥疹的變化情況，隨機分成2組每組各28人，分中醫外治榦預組及空白對照組。治療2週：齣疹的患者實驗組1級藥疹率50%，2級39.3%，3級10.7%，實驗組藥疹情況控製于1級（P＜0.05），實驗組2級、3級藥疹的髮病率顯著低于對照組（P＜0.05）。治療6週：實驗組齣現1級藥疹35.7%，2級50%，3級14.3%；對照組3級42.9%，4級14.3%，實驗組藥疹控製在1級與2級（P＜0.05），3級藥疹的髮病率顯著低于對照組（P＜0.05）。結論：本研究錶明，藥疹與尼妥珠單抗藥效無明顯對應關繫，同時活針藥結閤法可顯著改善由于尼妥珠單抗聯閤化療產生的藥疹。
목적：관찰매화침고자연합활혈해독중약용우치료니타주단항연합화료과정중반응성약진，이기위경호적제고만기종류환자약물의종성급생활질량제공론거지지。방법：90례만기종류환자균접수니타주단항연합기타화료약적치료，2주후평개안RECIST표준실체류정황，병근거시부산생약진장기수궤분위실험조급대조조。실험조행매화침국부고자연합백화사설초、고삼등활혈해독약물진행간예，대조조행생리염수간예。경과2주여6주적종합치료재차평고약진변화정황；약진표준삼고가나대국립암증연구소확대통용성표준（NCIC GTG분급）。결과：56례유약진발생，차기실체류평고공제솔여유효솔여무약진발생병례무명현차별；진일보평고56례입조약진환자불동처리후약진적변화정황，수궤분성2조매조각28인，분중의외치간예조급공백대조조。치료2주：출진적환자실험조1급약진솔50%，2급39.3%，3급10.7%，실험조약진정황공제우1급（P＜0.05），실험조2급、3급약진적발병솔현저저우대조조（P＜0.05）。치료6주：실험조출현1급약진35.7%，2급50%，3급14.3%；대조조3급42.9%，4급14.3%，실험조약진공제재1급여2급（P＜0.05），3급약진적발병솔현저저우대조조（P＜0.05）。결론：본연구표명，약진여니타주단항약효무명현대응관계，동시활침약결합법가현저개선유우니타주단항연합화료산생적약진。
Objective:To observe the effect of percussopunctator combined with Herbs (promoting blood circulation and detoxication, Huo-Xue-Jie-Du) on epispasis induced by Nimotuzumab combined with Chemotherapy. The aim of this study is to improve the drug dependence and their life quality of advanced cancer patients. Method: We selected 90 patients who received the combined therapy of Nimotuzumab&Chemotherapy. The solid tumor was detected by RECIST standard, and the epispasis patients would be separated into two groups, experimental group vs controls. The experimental group was to intervened with percussopunctator combined with Herbs, such as oldenlandia diffusa, sophora flavescens ait et al. The controls were intervened with physiological saline. 6 weeks later, solid tumor and the epispasis was detected according to NCIC GTG. Results:56 patients suffered epispasis, while the solid statue was no different. We further treated the epispasis by Chinese medicine. Both the experimental group and the control group have 28 patients. 2 weeks:The epispasis of experimental group was 50%, second epispasis 39.3%, third degree 10.7%; first degree epispasi was more in experimental group (P<0.05) ; compared with controls, second and third degree epispasis was lower (P<0.05). 6 weeks: The first degree epispasis of experimental group was 35.7%, second epispasis 42.9%, third degree 14.3%; first and second degree epispasi was more in experimental group (P<0.05). Compared with controls, third degree epispasi was lower in experimental group (P<0.05);and there was no fourth degree. Conclusion: There is no direct connection between epispasis induced by Nimotuzumab; the treatment of percussopunctator combined with Herbs got its effect on epispasis induced by Nimotuzumab combined with Chemotherapy.
